XSES
569
Market cap27mUSD
Sep 17, Last price
0.07SGD
1D
-1.45%
1Q
-15.00%
Jan 2017
-38.18%
Name
Vicplas International Ltd
Chart & performance
P/E
—
P/S
0.29
EPS
—
Div yield, %
—
Shrs. gr., 5y
0.16%
Rev. gr., 5y
5.65%
Revenues
121m
+17.99%
Net income
-2m
L+73.05%
CFO
388k
-94.23%
Dividend
Jan 09, 20240.0045 SGD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Vicplas International Ltd, established in Singapore in 1993, operates as an investment holding company with key business segments in medical devices and piping systems. The company's geographical reach includes Singapore, Malaysia, the People's Republic of China, and the United Kingdom. Its piping division focuses on the manufacturing, trading, and distribution of a variety of piping solutions. These systems are utilized for diverse applications such as waste and potable water management in residential, educational, commercial, and industrial settings; conduits for underground electrical and internal building wiring; and data and signal lines for telecommunication providers. Additionally, Vicplas is engaged in the design, development, production, and assembly of both sterile and non-sterile medical devices. The company also offers specialized project design and engineering services. Vicplas International Ltd is a subsidiary of Venner Capital S.A.
Key people
Independent Non-Executive Chairman of the Board · since 2009
Liang Cheng
Chief Executive Officer · since 2018
Ying Hui Gan
Chief Financial Officer · since 2016
Walter Tarca
Corporate Executive - President of the medical devices segment · since 2016
Hsheng Cheng
Group Operations Director · since 2016
Chin Liang Toon
Director - Technical · since 2015
Siew Peng Au
Company Secretary · since 2012
Christopher Paul Lee
Non-Executive Director · since 2013
Cher Yan Ng
Independent Non-Executive Director · since 2010
Valuation
Title SGD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑07 | 2024‑07 | 2023‑07 | 2022‑07 | 2021‑07 | 2020‑07 | 2019‑07 | 2018‑07 | 2017‑07 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||